

Oncology Advisory Committee

November 15, 2022

MEDITECH



Our Mission

The ONCAC mission is to **advance oncology informatics** throughout healthcare organizations and to **enhance safety and efficiency of oncology practices**. The ONCAC committee members will serve as subject matter experts and provide guidance, recommendations, and conceptualization on Oncology Best Practices through the use of MEDITECH software and provide feedback for the future design of the Oncology application.



External Members

- Gary Anderson, MN
- Dr. Trevor Bayliss, MA
- Jill Blankinship, IN
- Lauren Cox, MO
- Robbie Espejo, OH
- Alli Evert, OH
- Stacey Francis, MA
- Joo Hyun Greenwood, OH
- Amanda Gutshall, IA
- Kaiser Luebke, AR
- John Heeren, NJ
- Wendy McIntyre, IL
- Christine Mitry, ON
- Dana Morrison, MA
- Tami Morsching, MN
- Sandy Mulford, OH
- Paula Patton, AR
- Travis Reeves, IN
- Dawn Scott, ON
- Dr. Gautam Sudan, ON
- David Thompson, MA
- Joshua Vestal, KY
- Jodi Wieczorek, MN
- Suzanne Woodbury, MA
- Dr. Yendala, AR

Today's ONCAC Agenda

- Smart Pump Infusion Integration
- Drug Shortages
- Clinical Trials
- Development Corner
- Inpatient Ordering Demonstration





Smart Pump Infusion Integration

Emily Pacheco-Valente RN, Product Manager



Smart Pump Infusion Integration Features

- Bidirectional integration
- Barcode scanning capability of Smart Pump Device
- Auto-Population of MEDITECH order data onto the pump
- Capturing Infusion Start and Stop Times
- Population of primary and secondary infusion pump data onto MAR, IV Flowsheet and Specialty Care flowsheet
- Accommodation of continuous and intermittent infusions
- EDM/ONC/SUR/PCS/CC/L&D/Expense Patient Care access



Smart Pump Infusion Integration

Home Orders Discharge Sign Menu Settings Close
 Patient Verified
 BSA:1.81m² z BMI:24.2kg/m²
 MR00107391 D45648457

Rate Precision IV Site Intervention Mode Hide Text Recall Cancel OK

@ Titrate IV DAILY SCH
 Current Dose: 2 mcg/kg/min, 4.2 mls/hr
 Bag Volume: 250 mls
 Duration: Titrate
 Dosing Weight: 70 kg
 Trade: Dobutamine 500 mg-D5w 250 ml

Source	Thu Mar 4 7:04 am by PJF	Thu Mar 4 7:09 am by PJF	Thu Mar 4 7:10 am by PJF
Dobutamine HCl in Dextrose 5 % 500 mg In 250 ml @ 2 ...			
Assessments			
IV Site			
Intake			
Intake	0.3	0.3	0.1
Cumulative Intake (bag)	0.3	0.3	0.4
Cumulative Intake (Rx)	0.3	0.3	0.4
*Container Volume	250	249.7	249.6
Waste Amount	0	0	0
Dosing			
Dose Rate	2	4	4
(mcg/kg/min)			
*Infusion Rate	4.2	8.4	8.4
(mls/hr)			
Cumulative Dose (mg)	0.6	0.6	0.8
Increase/Decrease	Started	Increased	Running



Refer to manufacturers' full Prescribing Information for Dobutamine HCl Injection

Early Adopter Update



- Two Early Adopters for Baxter Spectrum IQ Pump
- Available in Expanse, priority pack to be determined
- Requirements:
 - LIVE with or implementing PCS or Expanse Patient Care, BMV, MAR and IV Flowsheet
 - LIVE with Baxter Spectrum IQ Large Volume Pumps
 - Wireless Network

Vendor Integration



- Baxter
 - Spectrum IQ Pumps
 - Novum IQ Pumps
- BD Care Fusion
 - Alaris Smart Pumps
- ICU Medical (Hospira)
 - Plum 360 Pumps
- B. Braun
 - Infusomat Space Pumps



Drug Shortages

Emily Villeneuve, Implementation Specialist



What Types of Drug Shortages are our Customers Experiencing?

In an ever-changing medical landscape, our customers are experiencing both **short-term** and **long-term** drug shortages.

Short-Term Drug Shortages

- Pharmacy staff should swap medication orders prior to verification.
- Changes have been made to maintain the link between Pharmacy and the Oncology Orders Panel (**CLIN-11946**).

	11/04/2022 Fri
▼ Breast cancer - Stage IV	
HER2 negative: Adjuvant AC Q21D then PACL Weekly	<input type="button" value="Dx/TNM"/> <input type="button" value="T"/> <input type="button" value="C"/> <input type="button" value="I"/>
Chemo <input type="button" value="Edit Seq"/> <input type="button" value="Add More"/>	C 5 Day 1
▼ Chemotherapy	
cyclophosphamide (Cytoxan)	1,050 mg IV 600 mg/m ²
DOXOrubicin hcl (Adriamycin)	105 mg IVP 60 mg/m ²
▼ Laboratory	
Complete Blood Count Auto Diff	Stat
Comprehensive Metabolic Panel	Routine

Long-Term Drug Shortages

- Consider updating Drug Product Map entries to include in-stock medication orders.
- Drug Product Mapping is evaluated at the time of ordering, so patients with previously ordered cycles will need to be managed (**IDEA-34654**).

From Dose	* Thru Dose	* Dose Units	Form	Direction	Route
0	500	MG			
500	1,000	MG			

+ → ↕ ✕

Location

Pharmacy Site

* Rate

Duration

Premix Fluid

IV Fluid

* Volume

Units

Round To

Medication Order	* Strength Multiplier	Amount
Doxorubicin HCl 50 MG/25 ML VIAL [DOXO50VI12]	12	600 MG
Doxorubicin HCl 20 MG/10 ML VIAL [DOXO20VI]	20	400 MG

Suggested Workflow

- **Report ID 02411** can be found on our Oncology Product Resource page. This report will identify a list of treatment plans that contain the affected Drug Product.
- With **CLIN-229883**, this report will be available to add to your users' Menu Procedure Access.

[MENU](#) [Regulatory](#) [Release Doc Search](#) [Knowledge Base](#) [Seminars](#) [Collaborative Solutions](#)

MEDITECH Report Archive Report Information

Report ID: 02411 Product Line(s): Expanse Application: ONC Reporting Tool: Report Designer Category: Dictionary Report Report Name(s): Oncplandrugmaps OncAmbDrugMapOncPlanDict OncPlanDictOrderSets	Submitted By: Kyle Dimock Date: 12/3/2021 Organization: Meditech Email Address: kdimock@meditech.com
--	---

Report Description

Three reports for listing ONC Treatment Plan Dictionary entries that contain the report selection for either Drug Product Map, Drug Product Map(AMB), or OM Order Set. The reports will list the treatment plans that have these selections added on the 'Orders' tab of the treatment plan dictionary.

[Download](#)

Suggested Workflow

Return To Home Chart Document Orders Oncology

EMILY VILLENEUVE

All Onc Appoint... 5 All Treatment A... 8 **ONC Treatme... 20**

Name	Appt	Location	Onc Tx Plans	Tx Plan Review	MAR
Age BirthSex	Time	Care Area	Diagnosis	Cycle Review	
Birthdate	Onc Status Event	Nurse	Orders Flag	Med Review	
Registration Sta...	Time in Status	Provider			
<input type="checkbox"/> Glazer, Jeffrey	Chemo 1 hr 10:00	Atlantic Cancer ...	Cisplatin & Carb... Bladder Cancer	Treatment Plan ...	
70 M	Booked				
> PRE RCR		Gutknecht, Jenny			
<input type="checkbox"/> Gandolph, Julia	Chemo 1 hr 11:00	Atlantic Cancer ...	J Gutknecht Trea... Bladder Cancer		
70 F	Booked		Ack-Med		
> PRE RCR		Gutknecht, Jenny			
<input type="checkbox"/> Wallace, Jordan	chemo/infusion -... 12:00	Oncology Infusio...	Gemcitabine & C... Cervical cancer, ...		
26 F	Booked		Ack-Med	Med Reviewed	
> PRE RCR		JOBS, Meditech ...			

Return To **Status Board Selection Dictionary (TRNSTD22)**

ONC.TX - ONC Treatment Plans

Selection

Mnemonic: ONC.TX

Copy From

* Active: Yes

* Name: ONC Treatment Plans

Type: Status Board

Field/Modifier	Operator
Onc Cycle Treatment Plan	Include List

Include List

+ x



Discussion: Clinical Trials

Hannah Schwartz, Senior Specialist

Clinical Trial Indicators

E Treatment Plan Dictionary (DEV.US) More Help HS User Close

Main Cycles Orders MAR Sequence Items Associations

Treatment Plan

Mnemonic

Active

Name

Clinic

Clinical Trial Yes No

Custom Data Screen

BSA Method

Inpatient Hold Queue Yes No

Override Drug Interactions Yes No

Override Duplicate Interactions Yes No

Oral Med Flowsheet Display

Alias

Orderable Yes No

Comment

Version

Flowsheet Display

Diagnosis

Orders Panel Label Sequence

Indication

Restrict by Location

Restrict by Provider

History Plan Protocol Plan Citations Plan User Notes Cancel Save ? 🔒 📧 ⚠️

View
New
Edit
Report

Clinical Trial Indicators

E Return To **Drug Product Map Dictionary (DEV.US)** More Help HS User X Close

Main | Product Map | Oncology | Banding

Drug Product Map

Mnemonic

* Active

Display Name

Chemotherapy Medication Yes No

Clinical Trial Medication Yes No

Alternative Product Map

Pha Type

View
Edit
Report

History Cancel Save ? 🔒 📧 ⚠️

Clinical Trial Indicators

E Return To Chart Oncology Chart Viewer More Help MJ User Close

March, Liz 39 F 11/21/1982 PRE ONCR ATLANTIC Resus Status Not Ordered No Hx Avail 1.65m 54.431kg BSA:1.59m² BMI:20.0kg/m² Allergy/Adv: Penicillins MG0000087110 MR00001062 D00000956

Cancel Save

New Plan

Provider: JOBS,Meditech DONOT EDIT

Diagnoses	Dx/TNM	Selected
Malignant neoplasm of breast		0
Malignant neoplasm of cervix		1


Suggested All Tumor Group

Plan: AC (Doxorubicin/CTX) Starts With Any Word

Select Plans for Diagnosis	Alias
HER2 negative: Adjuvant (1)	
<input checked="" type="checkbox"/> AC (DOXOrubicin/CTX) Q21D followed by PACLitaxel Weekly EV [Ver 1]	T A C
HER2 negative: Neoadjuvant (1)	
<input checked="" type="checkbox"/> AC (DOXOrubicin/CTX) Q21D followed by PACLitaxel Weekly EV [Ver 1]	T A C
No Indication (1)	
<input checked="" type="checkbox"/> AC (DOXOrubicin/CTX) Q21D followed by PACLitaxel Weekly EV [Ver 1]	T A C

Clinical Trial Indicators

E Return To Chart Oncology Chart Viewer More Help MJ User Close

 **March, Liz**
39 F 11/21/1982
PRE ONCR ATLANTIC

Resus Status Not Ordered No Hx Avail
1.65m 54.431kg BSA:1.59m² BMI:20.0kg/m²
Allergy/Adv: Penicillins

MG0000087110

MR00001062
D00000956

Options

Description	Diagnosis Date	Start Date	End Date	Status
Active Problems				
➤ Malignant neoplasm of breast	Dx/TNM			Add
➤ Malignant neoplasm of cervix	Dx/TNM			Add

Discussion Questions: Within Your Facility

- What are your workflows for clinical trials onsite?
- What is the process for identifying appropriate trials for your patient, and how and where do you keep track of this?

Discussion Questions: Outside Your Facility

- What is the process for current patients interested in a clinical trial at another facility?
- Do your providers remain engaged in the care or oversight of these patients if they do transfer to a different facility for a clinical trial?



Development Corner

Michelle Nabors, Senior Supervisor Development

Emily Pacheco-Valente, Product Manager

Libby Leach, Software Designer





Oncology Development Roadmap

Complete

- **Inpatient Chemo Administration improvements**
- Evaluate PHA Site at Broadcast
- Accommodate Problem Status Changes for Treatment Plan Ordering

In Process

- Genomics Integration and Decision Support
- Accommodate Edits to Ambulatory Meds made outside of ONC
- AJCC Staging API v2 Updates
- Regimen Ordering Research (Oncology Ordering in Web)

Upcoming

- eClaims interface in Ontario
- e-Prescribing for Ambulatory Meds / Amb Drug Products in Treatment Plans

Determining

- Project Plan for Regimen Ordering (Oncology Ordering in Web)
- More Flexibility to Transition Orders, and Evaluate Drug Product Mapping at Broadcast
- Streamline ordering of Carboplatin
- Exposing Oncology patient data via APIs (mCODE)

Inpatient Demo (Libby Leach)

CLIN-174879

This Inpatient Ordering enhancement focused on the needs of Pharmacy and Nursing when Oncology patients are admitted for treatment.

- Lack of Start and Stop Dates/Times
- Multiple RXs for one order
- The difference between the Oncology MAR and the acute MAR
- Lack of Pending functionality for Oncology orders

Inpatient Ordering

Difference between Expanse 2.1 and 2.2

- Access to the Hold Queue
 - Oncologist - Ambulatory > Acute Status Board > Hold Queue
 - Pharmacist - two options
 - XPC Status Board > Hold Queue data item
 - Pharmacy Desktop > Patient Profile > Chart > Hold Queue
 - Infusion Nurse - XPC Status Board > Hold Queue Data Item

Development Corner: Active Research

- Genomics and Oncology
 - Designer: Heidi Sokoloski - hsokoloski@meditech.com
- Oncology Ordering in the Web
 - Nate Mettille or Michelle Nabors
- Accommodate Edits to AMB Meds
 - Designer: Libby Leach - eleach@meditech.com

General Oncology Development contacts:

Nate Mettille
Manager Development, Oncology
nmettille@meditech.com

Michelle Nabors
Senior Supervisor Development, Oncology
mnabors@meditech.com

Emily Pacheco-Valente, BSN, RN
Product Manager
epacheco@meditech.com

Questions?

**Next ONCAC meeting
2023**



Oncology Resources

- [Oncology Advisory Committee \(ONCAC\) Webpage](#)
- [MEDITECH On Demand](#)
- [Oncology Featured Knowledge Base Articles](#)
- [Product Resource Pages](#)
 - **All Product Lines available**
- [Expanse End-User Based Roles Resources](#)



Thank You!

MEDITECH